Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 11, 1998

View Archived Issues

Nycomed Amersham files for approval of novel PD diagnostic

Targeted Genetics initiates phase I trials of aerosolized gene therapy for treatment of CF

Lorus Therapeutics announces final phase I/II pancreatic cancer trial data

Phase I clinical trials of female sexual dysfunction Rx commence

Two NIH grants awarded to Atrix for preclinical studies on Atrigel polymer system

Hoechst Supervisory Board approves demerger and merger proposals

Quinolinomorphinans for ischemic, hemorrhagic, traumatic or degenerative brain disorders

Adenosine absorption inhibitors from Kyowa Hakko useful as antiinflammatories, cardioprotectants

Another series of adenosine kinase inhibitors patented by Abbott

Noninfectious HIV particles as immunogens for treating or preventing HIV infection/AIDS

Novel topoisomerase inhibitor of microbial origin characterized at Kumamoto University

SB-207499: confirmation of PDE4 inhibition as a novel approach to respiratory disorders

News from World Asthma Meeting: Saiboku-to holds promise in bronchial asthma

DuPont files NDA for its multiapplication ultrasound contrast agent

Effects of calcium sensitization modulator Y-27632 on human bronchial tissues and pulmonary artery

Zeneca and Amersham Pharmacia Biotech will collaborate on proteomics research

Ebastine reported at World Asthma Meeting to have potential in allergic inflammatory conditions

DDE-261: a novel gigantecin analogue in early development at Wayne Hughes Institute

FDA approves Rebetron combination therapy for previously untreated HCV patients

Mouse studies indicate that IL-12 gene therapy is a feasible and effective treatment for AML

Status of FluMist influenza vaccine updated by Aviron

Genzyme Transgenics to develop monoclonal antibodies for Centocor

GH secretagogue and SERM show additive effects in ovariectomized rats

Strategic alliance formed with SB for intranasal flu vaccine in development at BioChem Pharma

Ariad initiates phase I trial with AP-1903 for treatment of GVHD

Cytogen obtains expanded rights to samarium Sm 153 lexidronam for RA

Decitabine considered a promising treatment option for high-risk patients with MDS

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...